Wednesday - April 29, 2026

Category Archives: Marketing & Sales

Sandwich Panels Market Valued at USD 16.52 Billion in 2026 to Witness 5.12% CAGR Through 2031 Fueled by Industrial and Cold Chain Expansion

Sandwich Panels Market Explore the Sandwich Panels market (2026–2031) with Mordor Intelligence. Get in-depth insights on market size, share, revenue, segments, key drivers, latest trends, and growth opportunities shaping the future of sustainable construction. The Sandwich panels Market continues to … Continue reading →

DigiMarCon Singapore 2026 Returns to Singapore, Bringing the Future of Digital Marketing to the Global Stage

Singapore – DigiMarCon Singapore, the premier digital marketing, media, advertising, and business conference and exhibition in the Singapore, will return August 26-27, 2026, at the Four Points by Sheraton Singapore Riverview Hotel in Singapore. The three-day event will unite marketers, … Continue reading →

Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics

The Key Facioscapulohumeral Muscular Dystrophy Companies in the market include – Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics, and others. DelveInsight’s “Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Facioscapulohumeral … Continue reading →

Chronic Myeloid Leukemia Pipeline Grows as 20+ Pharma Companies Advance Novel Blood Cancer Therapies, Finds DelveInsight | Renascience, Novartis Pharmaceuticals, Terns Pharmaceuticals

Chronic Myeloid Leukemia (CML) Pipeline Insights There are 20+ key companies, including Renascience, Novartis Pharmaceuticals, Terns Pharmaceuticals, Enliven Therapeutics, MacroGenics, Kartos Therapeutics, AOP Orphan Pharmaceuticals, and others, developing therapies for Chronic Myeloid Leukemia, with Renascience having its CML drug candidate … Continue reading →

Crohn’s Disease Pipeline Shows Strong Momentum as 90+ Pharma Companies Advance Novel Inflammatory Bowel Disease Therapies, Finds DelveInsight | AbbVie, Janssen, Merck, Takeda, Roche

Crohn’s Disease Pipeline Insight There are 90+ key companies, including AbbVie, Janssen, Merck, Takeda, Roche, AgomAb Therapeutics, Pfizer, Amgen, and others, developing therapies for Crohn’s disease, with companies like Janssen and Roche having candidates in the most advanced Phase III … Continue reading →

wAIHA Treatment Landscape: FDA Grants Priority Review to IMAAVY, Potential First Approved Therapy | Industry Insights on Market Impact, Competitive Landscape and Pipeline

Beyond wAIHA, nipocalimab is being studied in several other autoantibody-mediated diseases, including Sjögren’s disease, lupus, and generalized myasthenia gravis (where it is already approved). This multi-indication potential highlights the versatility of FcRn inhibition as a therapeutic platform for rare and … Continue reading →

Medullary Thyroid Cancer Pipeline Set for Strategic Expansion Through 2026 with 10+ Emerging Therapies and Robust Innovation from Bayer Healthcare and Applied Pharmaceutical Science | DelveInsight

Medullary Thyroid Cancer Pipeline Key Medullary Thyroid Cancer Companies include Bayer Healthcare, Applied Pharmaceutical Science, and others. The Medullary Thyroid Cancer therapeutic landscape is undergoing a significant transformation, driven by advancements in molecular oncology, targeted therapies, and precision medicine. Leading … Continue reading →